Metronomic scheduling: the future of chemotherapy?
- 1 December 2001
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 2 (12), 733-740
- https://doi.org/10.1016/s1470-2045(01)00587-3
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- The microenvironment of the tumour–host interfaceNature, 2001
- Pharmacogenetic applications of the Human Genome projectNature Medicine, 2001
- Chemotherapeutic drugs—more really is not betterNature Medicine, 2000
- Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceJCI Insight, 2000
- Tumor angiogenesis: past, present and the near futureCarcinogenesis: Integrative Cancer Research, 2000
- Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy?Advances in Enzyme Regulation, 1998
- A cancer therapy resistant to resistanceNature, 1997
- Shifting the cancer paradigm: must we kill to cure?Journal of Clinical Oncology, 1995
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agentsBioEssays, 1991
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971